Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia
Status:
Completed
Trial end date:
2017-12-22
Target enrollment:
Participant gender:
Summary
Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic
hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening.
There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one
publication); there is more experience with octreotide, both in adults and children
successful interventions with octreotide in hyperinsulinemic hypoglycemia have been
published. Pasireotide via its different somatostatin receptor binding profile has clear
effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia.
This mode of action (especially the effects on insulin and incretin secretion) could be very
useful in the setting of hyperinsulinemic hypoglycemia.